Myelodysplastic Syndromes (MDS)

Human HSPCs clones balance stochastic diversification with cytokine-induced differentiation

Original Publication Date

July 28, 2026

Article Source

External Web Content

Key Points cHSPCTrack uses circulated human HSPCs to reconstruct clonal differentiation dynamics Human HSPCs clones differentiation varies stochastically in lineage output and differentiation rate even in controlled isolated environments Hematopoietic stem and progenitor cells…

The NLRC4 Inflammasome Drives Myelodysplastic Syndrome by Linking Epigenetic Reprogramming and Innate Immune Signaling

Original Publication Date

July 24, 2026

Article Source

External Web Content

Key Points Chronic inflammation promotes transient myeloid differentiation in Tet2-deficient HSPCs, but accelerates HSC exhaustion and MDS development. NLRC4 inflammasome activation drives this process; Nlrc4 deletion delays MDS development and improves survival in Tet2-deficient…

Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes

Original Publication Date

July 25, 2026

Article Source

External Web Content

Abstract POEMS syndrome is a rare multisystem plasma cell disorder for which evidence guiding management is largely derived from single-center retrospective series. We conducted a retrospective multicenter study including all consecutive patients diagnosed between January 1995…

Patient and Caregiver Involvement With Prior Authorization and Care Delivery and Delays

Original Publication Date

July 23, 2026

Article Source

External Web Content

Introduction Payers employ health care utilization–management strategies, including prior authorization (PA), to limit costs and promote evidence-based, guideline-concordant care. However, PA may be inconsistently applied and associated with patient confusion and frustration.1-3…

Hypomethylating agents–venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT

Original Publication Date

July 22, 2026

Article Source

External Web Content

Key Points HMA-VEN is well tolerated in patients with AML/MDS who relapsed after alloHCT. HMA-VEN is effective for relapsed AML/MDS after alloHCT, even in patients who have failed prior VEN-based regimens. Abstract Relapse after allogeneic hematopoietic cell transplantation…

Insights to provider practice of germline testing for inherited hematologic malignancy predisposition syndromes to inform hematopoietic stem cell transplantation

Original Publication Date

August 10, 2026

Article Source

External Web Content

Highlights -Considerable heterogeneity exists in germline testing implementation across hematopoietic stem cell transplantation centers in the United States. -Lack of standardized protocols affects the timing of testing and inconsistent sample collection workflows. -Barriers to…

Getting the Right Diagnosis, from the 2026 AAMDSIF New Brunswick Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Dr. Virian Serei discusses how bone marrow failure is diagnosed, including the tests and evaluations used to receive a diagnosis of of aplastic anemia, myelodysplastic syndromes (MDS), or paroxysmal nocturnal hemoglobinuria (PNH).

Is a Transplant Right for Me? Session from the 2026 AAMDSIF New Brunswick Patient-Family Conference

Thumbnail for video Watch Now

Topic(s)

Aplastic Anemia

Bone Marrow Transplant

Myelodysplastic Syndromes (MDS)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Presenter(s)

Srinivasa Reddy Sanikommu, MD

Dr. Srinivasa Samikommu discusses bone marrow transplant, the transplant process, how doctors determine if it may be right for a patient and what you as a patient need to consider before moving forward with a transplant. The session was recorded at the 2026 AAMDSIF New Brunswick…

MDS: Lower Risk, Higher Risk, and MDS/MPN Overlap - 2026 New Brunswick Patient-Family Conference

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Presenter(s)

Xiaoyi Chen, MD, PhD

Payal Sojitra, MD

Drs. Xiaoyi Chen and Payal Sojitra discuss diagnosis approaches, key differences and treatment considerations for Lower-Risk MDS, Higher-Risk MDS, and MDS/MPN Overlap. The session was recorded live at the 2026 AAMDSIF New Brunswick Patient and Family Conference.

Myelodysplastic Syndromes (MDS)

Human HSPCs clones balance stochastic diversification with cytokine-induced differentiation

The NLRC4 Inflammasome Drives Myelodysplastic Syndrome by Linking Epigenetic Reprogramming and Innate Immune Signaling

Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes

Patient and Caregiver Involvement With Prior Authorization and Care Delivery and Delays

Hypomethylating agents–venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT

Insights to provider practice of germline testing for inherited hematologic malignancy predisposition syndromes to inform hematopoietic stem cell transplantation

Getting the Right Diagnosis, from the 2026 AAMDSIF New Brunswick Patient and Family Conference

Is a Transplant Right for Me? Session from the 2026 AAMDSIF New Brunswick Patient-Family Conference

MDS: Lower Risk, Higher Risk, and MDS/MPN Overlap - 2026 New Brunswick Patient-Family Conference

2026 Houston Patient and Family Conference

Website Feedback

Patient Helpline